25 July 2022 - Reimbursement for Vascepa in Canada is now at more than 65% for publicly covered lives and private ...
18 July 2022 - Effective today, the Province will pay for the cystic fibrosis drug Trikafta for children aged six to ...
13 July 2022 - Canada has seen a significant improvement in the number of Canadians eligible for some form of prescription ...
11 July 2022 - Children with cystic fibrosis can now live 'longer, healthier and fuller lives,' says advocate. ...
11 July 2022 - In July 2021, the Government of Canada approached CADTH to develop a recommended framework for creating and ...
7 July 2022 - Vertex Pharmaceuticals today announced that it has signed a letter of intent with the pan-Canadian Pharmaceutical ...
15 June 2022 - New drug price regulations set to come into effect next month could lower spending on patented ...
10 June 2022 - CADTH is pleased to announce the four successful core network partners of its inaugural post-market drug ...
24 May 2022 - Quebec becomes the first province to reimburse Vascepa for the reduction of cardiovascular risk in patients with ...
20 May 2022 - CADTH does not accept new evidence demonstrating Spinraza's effectiveness and safety for treating spinal muscular atrophy – ...
17 May 2022 - Teva Canada welcomes the recently announced public formulary coverage for Ajovy (fremanezumab) by Ontario, British Columbia, ...
28 April 2022 - CADTH is expanding its scientific advice program to include applications for advice on real world evidence generation ...
12 May 2022 - What began with a promise to protect Canadians ended with a commitment to support pharmaceutical companies. ...
3 May 2022 - Boehringer Ingelheim is pleased to announce that Ofev (nintedanib), is now available for public reimbursement in Quebec, ...
28 April 2022 - An average of nine new medicines per quarter have been approved in Canada through the pandemic, ...